SymBio Pharmaceuticals Limited revised earnings guidance for the fiscal year ending December 31, 2023. For the period, the company revised net sales to JPY 5,589 million from JPY 5,603 million, operating loss to JPY 811 million from JPY 680 million, loss attributable to owners of parent to JPY 1,962 million from JPY 1,291 million and loss per share to JPY 49.19 from JPY 32.54.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
175 JPY | -1.69% | +0.57% | -29.15% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-29.15% | 50.92M | |
+25.61% | 661B | |
+26.74% | 566B | |
-6.64% | 352B | |
+19.42% | 332B | |
+3.49% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.75% | 145B |
- Stock Market
- Equities
- 4582 Stock
- News SymBio Pharmaceuticals Limited
- SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023